Literature DB >> 26899187

Targeting the Folate Receptor: Effects of Conjugating Folic Acid to DOX Loaded Polymeric Micelles.

Mohamed A Elkhodiry, Ghaleb A Husseini1, Diana Velluto.   

Abstract

In this paper, we report on a potential cancer drug delivery system that utilizes the ligand targeting of the folate receptor. Our drug delivery system consists of Pluronic-P105 micelles, targeted with folic acid moieties. A melanoma folate positive (FR+) (B16-F10), and a fibroblast folate negative (FR-) (NIH-3T3) cell lines are used to compare the cellular accumulation of a chemotherapeutic drug (Doxorubicin) when the delivery is mediated by folated Pluronic P105 micelles. In order to obtain a proper comparison, we corrected for the quenching of Doxorubicin by folic acid molecules and illustrated the significant effect of quenching on the analysis of similar systems. Results show an 80% increase in the accumulation of the antineoplastic agent in the FR+ cell line, when compared to the FR- cell line, thus providing evidence that the efficacy of Pluronic micelles, as drug delivery vehicles, can be enhanced via folic acid targeting.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26899187     DOI: 10.2174/1871520616666160219161600

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  2 in total

1.  Optimization and Characterization of Protein Nanoparticles for the Targeted and Smart Delivery of Cytochrome c to Non-Small Cell Lung Carcinoma.

Authors:  Vanessa Barcelo-Bovea; Irivette Dominguez-Martinez; Freisa Joaquin-Ovalle; Luis A Amador; Elizabeth Castro-Rivera; Kristofer Medina-Álvarez; Anthony McGoron; Kai Griebenow; Yancy Ferrer-Acosta
Journal:  Cancers (Basel)       Date:  2020-05-13       Impact factor: 6.639

2.  Folate-Decorated Cross-Linked Cytochrome c Nanoparticles for Active Targeting of Non-Small Cell Lung Carcinoma (NSCLC).

Authors:  Irivette Dominguez-Martinez; Freisa Joaquin-Ovalle; Yancy Ferrer-Acosta; Kai H Griebenow
Journal:  Pharmaceutics       Date:  2022-02-24       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.